Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

doi:10.1016/j.molcel.2021.09.005

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.

Molecular cell - 18 Nov 2021

Paes Dias Mariana, Tripathi Vivek, van der Heijden Ingrid, Cong Ke, Manolika Eleni-Maria, Bhin Jinhyuk, Gogola Ewa, Galanos Panagiotis, Annunziato Stefano, Lieftink Cor, Andújar-Sánchez Miguel, Chakrabarty Sanjiban, Smith Graeme C M, van de Ven Marieke, Beijersbergen Roderick L, Bartkova Jirina, Rottenberg Sven, Cantor Sharon, Bartek Jiri, Ray Chaudhuri Arnab, Jonkers Jos

Abstract excerpt

Inhibitors of poly(ADP-ribose) (PAR) polymerase (PARPi) have entered the clinic for the treatment of homologous recombination (HR)-deficient cancers. Despite the success of this approach, preclinical and clinical research with PARPi has revealed multiple resistance mechanisms, highlighting the need for identification of novel functional biomarkers and combination treatment strategies. Functional genetic screens...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA Ligase ATP

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lentivirus

Share to Mammary Neoplasms, Animal

Share to MRE11 Homologue Protein

Share to Poly-ADP-Ribose Binding Proteins

Share to Poly(ADP-ribose) Polymerase Inhibitors

Share to Triple Negative Breast Neoplasms

Share to Tumor Suppressor p53-Binding Protein 1

Source

Open in PubMed Open full text

Identifiers

PMID: 34555355
DOI: 10.1016/j.molcel.2021.09.005
PMCID: PMC9098260

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Loss of nuclear DNA ligase III reverts PARP inhibitor resistance in BRCA1/53BP1 double-deficient cells by exposing ssDNA gaps.PMID 34555355Read ↗

Loss of Nuclear DNA Ligase III Reverts PARP Inhibitor Resistance in BRCA1/53BP1 Double-deficient Cells by Exposing ssDNA GapsSemantic proximity Read ↗

Targeting DNA damage response pathways in cancer.Semantic proximity Read ↗

PARP inhibitor synthetic lethality reveals homologous recombination sub-pathway architectureSemantic proximity Read ↗

PARPi, BRCA, and gaps: controversies and future researchSemantic proximity Read ↗

Reversing regulatory safeguards: Targeting the ATR pathway to overcome PARP inhibitor resistanceSemantic proximity Read ↗

FANCA Deficiency Induces Oncogenic R-Loop Dependent Synthetic Lethality with PARP1 InhibitorsSemantic proximity Read ↗

Drug–gene Interaction Screens Coupled to Tumor Data Analyses Identify the Most Clinically Relevant Cancer Vulnerabilities Driving Sensitivity to PARP InhibitionSemantic proximity Read ↗

Drug-gene interaction screens coupled to tumour data analyses identify the most clinically-relevant cancer vulnerabilities driving sensitivity to PARP inhibitionSemantic proximity Read ↗

MiR223-3p promotes synthetic lethality in BRCA1-deficient cancers.Semantic proximity Read ↗

Mechanisms of PARP inhibitor resistance in cancer and insights into the DNA damage responseSemantic proximity Read ↗

Homologous recombination in cancer development, treatment and development of drug resistanceSemantic proximity Read ↗

XRCC1 prevents toxic PARP1 trapping during DNA base excision repairSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.